Track the company's progress on its compliance plan, particularly any capital raises or restructuring that could improve equity. Delisting risk remains significant if the plan fails, making PHGE a high-risk, event-driven trade. The extended timeline (2027) reduces near-term urgency.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 12 $0.5362entry
- T+1 · 5mo ago +3.49%α +1.72% · $0.5549
- T+5 · 5mo ago −3.04%α −3.71% · $0.5199
- T+20 · 4mo ago −56.73%α −58.51% · $0.2320
- T+60 · 2mo ago −71.09%α −74.36% · $0.1550
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BiomX Inc. received acceptance from NYSE American of its plan to regain compliance with continued listing standards, granting a plan period through September 25, 2027. The company had a stockholders' deficit of $(1.302 million) as of December 31, 2025 and losses in five recent fiscal years, leading to its non-compliance. While the plan acceptance provides a path to avoid delisting, the underlying financial weakness and high execution risk keep the outlook uncertain.
Key Facts
- NYSE American accepted BiomX's compliance plan on June 10, 2026, with a plan period through September 25, 2027.
- Non-compliance stemmed from stockholders' deficit of $1.302 million as of Dec 31, 2025 and losses from continuing operations in five recent fiscal years.
- The company's stock will continue trading with a .BC (below compliance) indicator during the plan period.
- If the company fails to regain compliance or make sufficient progress, delisting proceedings may be initiated.
Financial Impact
Stockholders' deficit of $1.302 million as of December 31, 2025, with ongoing losses from operations.
Risk Factors
- Failure to execute the compliance plan could lead to delisting and loss of liquidity.
- Continued operating losses may further erode stockholders' equity and worsen compliance.
- Going concern risk given historical losses and negative equity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-068026 |
| Document: ea029450701ex99-1.htm | 0001213900-26-068026 |
| Document: 0001213900-26-068026-index-headers.html | 0001213900-26-068026 |
| Document: 0001213900-26-068026-index.html | 0001213900-26-068026 |
| Document: 0001213900-26-068026.txt | 0001213900-26-068026 |
Track record
22 reports on PHGE
8 of 12 bullish or bearish reports moved the stock their way by T+1. Best: +62.36% at T+20 after the Jun 16, 2026 report. 8 of 12 went positive at some point.
Filters
- Oct 7, 20265w ago 8-K Neutral 4/10 Entry $0.3092 to $0.2915 ▼ −5.72% −5.30% vs SPY
- Oct 7, 20265w ago DEF 14A Bearish 6/10 Entry $0.3092 to $0.2915 ▲ +5.72% +5.30% vs SPY
- Sep 1, 202610w ago 8-K Neutral 3/10 Entry $0.1425 to $0.1421 ▼ −0.28% −1.33% vs SPY
- Aug 28, 202611w ago 8-K Neutral 4/10 Entry $0.1371 to $0.1430 ▲ +4.30% +4.99% vs SPY
- Aug 5, 202614w ago Press Release Bearish 5/10 Entry $0.1800 to $0.1598 ▲ +11.22% +11.06% vs SPY
- Jul 28, 202615w ago 8-K Bearish 8/10 Entry $0.1834 to $0.1830 ▲ +0.22% −1.32% vs SPY
- Jul 28, 202615w ago Press Release Bearish 7/10 Entry $0.1834 to $0.1830 ▲ +0.22% −1.32% vs SPY
- Jul 27, 202616w ago 424B5 Bearish 7/10 Entry $0.1834 to $0.1830 ▲ +0.22% −1.32% vs SPY
- Jul 8, 202618w ago Press Release Neutral 4/10 Entry $0.2758 to $0.2800 ▲ +1.52% +0.68% vs SPY
- Jul 2, 202619w ago 8-K Bearish 6/10 Entry $0.3190 to $0.3020 ▲ +5.33% +6.20% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers